文献速递骨质疏松与代谢性骨病

地舒单抗停药后高钙血症:系统综述与病例报告

Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case report.
PubMed 文献 · Osteoporos Int · 2026-01-22

该系统综述纳入截至2025年4月的病例报告,汇总4例骨质疏松女性在地舒单抗停药后出现高钙血症,均未预先使用双膦酸盐。高钙血症为轻至中度且无症状,伴骨转换标志物升高和甲状旁腺激素降低,部分患者发生多发椎体骨折。结论强调停药后序贯抗骨吸收治疗和密切监测的重要性。

要点

  • 地舒单抗停药后高钙血症罕见,通常轻微且无症状,反映破骨细胞反跳激活。
  • 4例患者均未预先使用双膦酸盐,停药3-11个月后出现高钙血症。
  • 强烈推荐地舒单抗停药后序贯抗骨吸收治疗并密切监测。

核心结论

  • 地舒单抗停药后高钙血症在骨质疏松中罕见,通常轻微,反映破骨细胞反跳激活。
  • 强烈推荐地舒单抗停药后序贯抗骨吸收治疗。

研究设计与样本

  • 基于PRISMA的系统综述,检索截至2025年4月,纳入描述骨质疏松患者地舒单抗停药后高钙血症的病例报告和系列,并报告1例额外病例。
  • 共3项研究(包含4名女性,年龄64-86岁)符合纳入标准。

主要发现

  • 所有患者均接受地舒单抗60 mg每6个月一次,持续3-10年,且既往未使用双膦酸盐。
  • 高钙血症(范围11.3-13.0 mg/dL)出现在停药后3-11个月,为轻至中度且无症状。
  • 骨转换标志物显著升高,完整甲状旁腺激素水平低或受抑制。
  • 两名患者发生多发椎体骨折。
  • 管理包括重新开始双膦酸盐或地舒单抗治疗。

临床怎么用

  • 骨质疏松患者地舒单抗停药后应序贯抗骨吸收治疗并密切监测血钙。
  • 停药后出现高钙血症时,可重新开始双膦酸盐或地舒单抗治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Discontinuation of denosumab may result in rebound bone resorption, fractures, and rarely hypercalcemia, a very uncommon manifestation. Our systematic review and case report highlight that although rare, calcium disturbances occur after treatment withdrawal. These findings emphasize the importance of sequential antiresorptive therapy and close monitoring in osteoporosis patients. BACKGROUND: Denosumab discontinuation has been associated with rebound bone resorption, rapid bone loss, and vertebral fractures. Hypercalcemia remains exceptional in postmenopausal osteoporosis. METHODS: We conducted a PRISMA-based systematic review up to April 2025, including case reports and series describing hypercalcemia after denosumab withdrawal in osteoporosis. We report one additional case. RESULTS: Three studies (encompassing four women, aged 64-86 years) met the inclusion criteria. All had received denosumab 60 mg every 6 months for 3-10 years, without prior bisphosphonate exposure. Hypercalcemia (range, 11.3-13.0 mg/dL), developed 3-11 months after discontinuation, was mild to moderate, and asymptomatic. Bone turnover markers were markedly elevated, with low or suppressed intact parathyroid hormone levels. Two patients sustained multiple vertebral fractures. Management consisted of reinitiation of bisphosphonates or denosumab. CONCLUSIONS: Hypercalcemia after denosumab withdrawal in osteoporosis is rare, typically mild, and reflects rebound osteoclast activation. Sequential antiresorptive therapy is strongly recommended following denosumab discontinuation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Menéndez JQ, García Tellado Á, Pardo Lleidas J, et al. Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case report. Osteoporos Int. 2026. PMID: 41571922. doi:10.1007/s00198-026-07854-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。